Dermacoat Skin Protectant Hand Cream "New Drug," FDA Determines
This article was originally published in The Tan Sheet
Executive Summary
Dermacoat Skin Protectant Hand Cream is an unapproved "new drug" and "may not be legally marketed in the United States without an approved new drug application," FDA's Dallas district office informed Irving, Texas-based NCH Corporation in a recent warning letter.
You may also be interested in...
Jergens Anti-Bacterial lotion
Prophylactic claims for product draw April 22 warning letter from FDA. Claims include "Your skin needs daily protection from...the bacteria and germs you encounter every day and...bonds to skin for germ protection." The agency states that "representatives for prophylactic antimicrobial barrier use...are not described in any of the rulemakings being considered under the [OTC] Review. Further, we are not aware of any substantial scientific evidence that Jergens Anti-Bacterial Antiseptic Lotion is generally recognized among scientific experts as safe and effective for these uses, and this product has not been marketed for a material time and to a material extent." As a result, the product, which contains benzalkonium chloride, is considered an unapproved new drug, according to FDA. Andrew Jergens is preparing a response. The agency sent a similar letter to Bristol-Myers Squibb in May 1998 for its Keri Anti-Bacterial Lotion ("The Tan Sheet" June 15, 1998, p. 3)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands